# A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis

> **NCT00641602** · PHASE4 · COMPLETED · sponsor: **AstraZeneca** · enrollment: 1000 (estimated)

## Conditions studied

- Erosive Esophagitis

## Interventions

- **DRUG:** Esomeprazole
- **DRUG:** Lansoprazole

## Key facts

- **NCT ID:** NCT00641602
- **Lead sponsor:** AstraZeneca
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2002-12
- **Primary completion:** 2003-08
- **Final completion:** 2003-08
- **Target enrollment:** 1000 (ESTIMATED)
- **Last updated:** 2009-03-26


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641602

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641602, "A Multicenter, Randomized, Double Blind, Double Dummy, Parallel-Group Efficacy Study Comparing 8 Weeks of Treatment With Esomeprazole Magnesium (40mg qd) to Lansoprazole (30mg qd) for the Healing of Erosive Esophagitis in Patients With Moderate or Severe Erosive Esophagitis". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT00641602. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*